9:51 AM
 | 
Feb 06, 2019
 |  BC Extra  |  Company News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >